Begin with IV amoxiclav, then use melanoma staging and dermatomyositis trial data to see where treatment narrows, escalates, or stays uncertain.
IV amoxiclav is not Pseudomonas or MRSA cover.
Start with IV amoxiclav. It is the clearest bedside listen today because it asks a practical question before any stewardship move: does this still look community acquired? That one decision changes whether stepping down from piperacillin-tazobactam, ceftriaxone, or a carbapenem makes sense, and it stops broad community cover being mistaken for Pseudomonas, MRSA, or ESBL cover.
Several of the other strong episodes also depend on getting the diagnosis, histology, or trial population clear before treatment changes. In melanoma, excision histology, Breslow thickness, ulceration, and nodal status decide whether wider excision, sentinel lymph node biopsy, follow-up, or adjuvant PD-1 treatment enter the plan. In dermatomyositis, VALOR shows skin benefit and steroid sparing, but only in active muscle-and-skin disease and without settling how brepocitinib should sit beside IVIG or conventional DMARDs. The neurology careers piece is the non-bedside listen, but useful for trainees and early-career neurologists. Carry one habit forward: before narrowing antibiotics, decide again whether the infection is still community acquired.
Start here: if a patient with community-acquired infection is still on piperacillin-tazobactam, ceftriaxone or a carbapenem, this gives a practical route to narrowing safely. The key is defining the syndrome first, then checking for coverage gaps such as Pseudomonas, MRSA, ESBL producers, or atypical pneumonia.
The trigger is rectal bleeding, haematuria or altered bowel habit years after pelvic radiotherapy. Start here for a practical guide to pelvic radiation disease, including toilet posture, loperamide, and when gastroenterology, urology or late-effects teams should be involved.
New myositis drugs are easy to overread from the headline result alone. This review separates skin response, muscle response, steroid sparing, infection risk, and the unanswered question of where brepocitinib sits beside IVIG and conventional DMARDs.
The outlier today is a career piece, but it is still useful for trainees and early-career neurologists. It pushes back against all-or-nothing thinking about research, links patient and advocacy-group work to meaning, and names post-training worry as a real early-career trap.
When a febrile patient on broad IV antibiotics starts to improve, stop and classify the infection again. If the story still fits community-acquired pneumonia, pyelonephritis, skin and soft tissue infection, or intra-abdominal infection, review cultures, check creatinine clearance, and ask whether IV amoxiclav is now the better fit.
When is IV amoxiclav a sensible de-escalation option?
When IV treatment is still needed and the syndrome still looks community acquired rather than hospital acquired. It is used here in pneumonia, pyelonephritis, skin and soft tissue infection, and intra-abdominal infection when the coverage fits.
What gaps stop IV amoxiclav being treated as universal cover?
Do not treat it as cover for Pseudomonas, ESBL-producing Gram-negative organisms, or MRSA. In community-acquired pneumonia, decide separately whether atypical cover is still needed.
Which melanoma findings on the excision report change what happens next?
Breslow thickness, ulceration, and nodal staging drive the next steps after excision. Around 1 mm thickness is where sentinel lymph node biopsy becomes relevant here.
.svg)